论文部分内容阅读
目的 评估膀胱灌注羟基喜树碱预防膀胱癌术后复发的疗效。方法 应用羟基喜树碱膀胱灌注预防膀胱癌术后复发并与MMC进行随机对照观察。结果 羟基喜树碱组治疗 2 3例 ,随访 6～ 36个月 ,复发 3例 ,复发率为 13 0 %。而MMC组治疗 2 2例 ,随访 7～ 36个月 ,复发 4例 ,复发率为 18 2 %。结论 提示HCPT的疗效与MMC相仿 ,而副作用明显减少 ,认为羟基喜树碱是目前预防膀胱癌术后复发较理想的药物之一。
Objective To evaluate the efficacy of intravesical instillation of hydroxycamptothecin in the prevention of postoperative recurrence of bladder cancer. Methods Intravesical instillation of hydroxycamptothecin for the prevention of postoperative recurrence of bladder cancer and randomized controlled clinical trials with MMC. Results Hydroxycamptothecin group of 23 cases of treatment, followed up for 6 to 36 months, 3 cases of recurrence, the recurrence rate was 13 0%. The MMC group of 22 cases of treatment, followed up for 7 to 36 months, 4 cases of recurrence, the recurrence rate was 18 2%. The results suggest that the effect of HCPT is similar to that of MMC, and the side effects are obviously reduced. Hydroxycamptothecin is considered as one of the ideal drugs to prevent recurrence of bladder cancer at present.